Risultati della ricerca - Birgit Bossenmaier

  • Mostra 1 - 14 risultati su 14
Raffina i risultati
  1. 1
    Acquired Resistance to Antibody-Drug Conjugates

    Acquired Resistance to Antibody-Drug Conjugates di Denis M. Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor

    Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor di Birgit Bossenmaier, Luitgard Mosthaf, Harald Mischak, A. Ullrich, Hans‐Ulrich Häring

    Pubblicazione 1997
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

    Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models di Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl, Max Hasmann

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Differential activities of protein tyrosine phosphatases in intact cells.

    Differential activities of protein tyrosine phosphatases in intact cells. di Reiner Lammers, Birgit Bossenmaier, D E Cool, N. K. Tonks, Joseph Schlessinger, E H Fischer, A. Ullrich

    Pubblicazione 1993
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

    Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. di G Kroder, Birgit Bossenmaier, Monika Kellerer, Edison Capp, B Stoyanov, A Mühlhöfer, Lucia Berti, Hiroyoshi Horikoshi, A. Ullrich, Hans-Ulrich Häring

    Pubblicazione 1996
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

    Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer di Denis M. Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Maja Weisser, Birgit Bossenmaier

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

    Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity di Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K. Bera, Masaki Terabe, Jay A. Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin‐Hsien Tai, Yoram Reiter, Ira Pastan

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

    RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation di Christian Mirschberger, Christian Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A. Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl‐Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab

    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab di Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116

    ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116 di Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj, Carolien P. Schröder, Linda Pot, Birgit Bossenmaier, Marlène Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G.W. Kosterink, Elisabeth G.E. de Vries

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy

    Characterization of a re‐engineered, mesothelin‐targeted<i>Pseudomonas</i>exotoxin fusion protein for lung cancer therapy di Frieder Bauss, Martin Lechmann, Ben‐Fillippo Krippendorff, Roland F. Staack, Frank Herting, Matthias Festag, Sabine Imhof-Jung, Friederike Hesse, Marc Pompiati, Gwendlyn Kollmorgen, Rita da Silva Mateus Seidl, Birgit Bossenmaier, Wilma Lau, Christian Schantz, Jan Olaf Stracke, Ulrich Brinkmann, Masanori Onda, Ira Pastan, Klaus Bosslet, Gerhard Niederfellner

    Pubblicazione 2016
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

    The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner di Janet K. Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales‐Kastresana, Thomas J. Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Hélène Lelièvre, Alix Scholer‐Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Rivière, Maximilien Grandclaudon, Markus Zettl, Rachida S. Bel Aiba, Christine Rothe, Véronique Blanc, Shane A. Olwill

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors di Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, Álvaro Taus, Martijn P. Lolkema, Emile E. Voest, Marlies H.G. Langenberg, Tania Fleitas, Andrés Cervantes, Maja J. De Jonge, Stefan Sleijfer, Morten Mau‐Sørensen, Marlène Thomas, Maurizio Ceppi, Georgina Meneses‐Lorente, Ian James, Céline Adessi, Francesca Michielin, K. Abiraj, Birgit Bossenmaier, Jan H.M. Schellens, Maja Weisser, Ulrik Lassen

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

    Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer di Denis M. Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy Gately, Clare Hughes, Anthony M. Davies, Thamir Mahgoub, Jo Ballot, Sinéad Toomey, Darran P. O’Connor, William M. Gallagher, Frankie A. Holmes, Virginia Espina, Lance A. Liotta, Bryan T. Hennessy, Kenneth J. O’Byrne, Max Hasmann, Birgit Bossenmaier, Norma O’Donovan, John Crown

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: